Madrigal Pharmaceuticals
Conshohocken, PA, USA
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). The Senior Product Manager (SPM), HCP Marketing (Non-Personal Promotion) will be a vital member on the US Marketing team focusing on healthcare professionals (HCPs). On March 14, 2024, Madrigal Pharmaceuticals received approval for RezdiffraTM (resmetirom) – the first FDA-approved treatment for noncirrhotic MASH with moderate to advanced liver fibrosis. This is truly...